Delving into the Latest Updates on Dongbao Zixing (Hangzhou) Biomedical Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Congenital Disorders

Skin and Musculoskeletal Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	7
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Synthetic peptide	2

Top 5 Target	Count

GIPR x GLP-1R	2
XO(Xanthine dehydrogenase)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
DPP-4 x SGLT1 x SGLT2	1
URAT1 x XO	1

主要研究目的： 1)定量分析男性健康受试者单次口服[14C]THDBH151后排泄物中的总放射性，获得人体放射性总回收率、放射性排泄数据和主要排泄途径； 2)定量分析男性健康受试者单次口服[14C]THDBH151后全血和血浆中的总放射性，获得全血（如适用）和血浆总放射性的药代动力学参数； 3)定量分析男性健康受试者单次口服[14C]THDBH151后人血浆、尿液和粪便的放射性代谢物谱，鉴定主要代谢产物，确定THDBH151在人体内的代谢途径及消除途径。次要研究目的： 1)考察全血和血浆中总放射性的分配情况； 2)采用经验证的液相色谱串联质谱法（LC-MS/MS）定量分析血浆中THDBH151及其代谢产物（如适用）的浓度，获得血浆中THDBH151及其代谢产物（如适用）的药代动力学参数； 3)观察男性健康受试者单次口服[14C]THDBH151后的安全性。

[Translation]

Main research objectives: 1) Quantitative analysis of the total radioactivity in the excreta of male healthy subjects after a single oral administration of [14C]THDBH151, to obtain the total recovery rate of human radioactivity, radioactive excretion data and the main excretion pathway; 2) Quantitative analysis of the total radioactivity in whole blood and plasma of male healthy subjects after a single oral administration of [14C]THDBH151, to obtain the pharmacokinetic parameters of the total radioactivity in whole blood (if applicable) and plasma; 3) Quantitative analysis of the radioactive metabolite profiles in human plasma, urine and feces of male healthy subjects after a single oral administration of [14C]THDBH151, to identify the main metabolites, and to determine the metabolic pathways and elimination pathways of THDBH151 in the human body. Secondary study objectives: 1) To investigate the distribution of total radioactivity in whole blood and plasma; 2) To quantitatively analyze the concentration of THDBH151 and its metabolites (if applicable) in plasma using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method to obtain the pharmacokinetic parameters of THDBH151 and its metabolites (if applicable) in plasma; 3) To observe the safety of [14C]THDBH151 after a single oral administration in healthy male subjects.

Start Date13 Sep 2024

Sponsor / Collaborator

Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

CTR20242389 / RecruitingPhase 1

在中国肥胖受试者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学特征和初步有效性的随机、双盲、安慰剂对照的Ib期临床试验

[Translation] A randomized, double-blind, placebo-controlled Phase Ib clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of multiple doses of THDBH120 for injection in obese Chinese subjects

主要目的：评估肥胖受试者多次皮下注射THDBH120后的安全性和耐受性。次要目的：评估肥胖受试者多次皮下注射THDBH120后的药代动力学（PK）特征；评估肥胖受试者多次皮下注射THDBH120后的药效动力学（PD）特征；评估肥胖受试者多次皮下注射THDBH120后的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of THDBH120 after multiple subcutaneous injections in obese subjects. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of THDBH120 after multiple subcutaneous injections in obese subjects; To evaluate the pharmacodynamic (PD) characteristics of THDBH120 after multiple subcutaneous injections in obese subjects; To evaluate the immunogenicity of THDBH120 after multiple subcutaneous injections in obese subjects.

Start Date18 Jul 2024

Sponsor / Collaborator

Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

CTR20241940 / RecruitingPhase 1

在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床试验

[Translation] A randomized, double-blind, placebo-controlled Phase Ib clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of THDBH120 for injection in Chinese adults with type 2 diabetes

主要目的：评估2型糖尿病患者多次皮下注射THDBH120后的安全性和耐受性；次要目的：评估2型糖尿病患者多次皮下注射THDBH120后的药代动力学（PK）特征；评估2型糖尿病患者多次皮下注射THDBH120后的药效动力学（PD）特征；评估2型糖尿病患者多次皮下注射THDBH120后的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of THDBH120 after multiple subcutaneous injections in patients with type 2 diabetes; Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of THDBH120 after multiple subcutaneous injections in patients with type 2 diabetes; To evaluate the pharmacodynamic (PD) characteristics of THDBH120 after multiple subcutaneous injections in patients with type 2 diabetes; To evaluate the immunogenicity of THDBH120 after multiple subcutaneous injections in patients with type 2 diabetes.

Start Date13 Jun 2024

Sponsor / Collaborator

Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

100 Clinical Results associated with Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

Login to view more data

100 Deals associated with Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Dongbao Zixing (Hangzhou) Biomedical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

IND Application

Phase 1 Clinical

3

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

THDBH151 ( URAT1 x XO )	Gout More	Phase 2
THDBH110 ( GLP-1R )	Diabetes Mellitus, Type 2 More	Phase 1
THDBH101 ( DPP-4 x SGLT1 x SGLT2 )	Diabetes Mellitus, Type 2 More	Phase 1
THDBH120 ( GIPR x GLP-1R )	Diabetes Mellitus, Type 2 More	Phase 1
THDBH121 ( GIPR x GLP-1R )	Diabetes Mellitus, Type 2 More	IND Application